Patients with advanced renal cell carcinoma: Immediate or delayed treatment? Study of a cohort of patients followed at Instituto Oncológico Henry Moore (IOHM)
| Autor: | Sandra L. Ares, Dario Niewiadomski, Edgardo G. J. Rivarola, Felipe G. Gercovich, Eduardo L. Morgenfeld, Claudia Lorena Acuna, Ernesto Gil Deza, Gaston Martin Reinas |
|---|---|
| Rok vydání: | 2017 |
| Předmět: | |
| Zdroj: | Journal of Clinical Oncology. 35:e16073-e16073 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2017.35.15_suppl.e16073 |
| Popis: | e16073 Background: Most of the treatment guidelines for advanced renal cancer (RCC) agree about what drugs must be used, but don’t indicate when the treatment should be started. This decision is left to the desire of the patient (pt) and/or the common sense of the doctor. The aim of this paper is to study which could be the best time of initiation of systemic treatment (Tx) in advanced RCC. Methods: Between 1/1/2001 and 11/30/2016, 828 patients diagnosed with RCC were followed at IOHM. We selected all pt with clear cell or papillary stage IV RCC who received systemic Tx; 80 pt met this inclusion criteria. We reviewed all the clinical records of this population and separated two groups according to the time of initiation of systemic treatment: Group A (Immediate = within three months of diagnosis) or Group B (Delayed = beyond three months of diagnosis). We compared the population’s characteristics and outcome of each group. Results: The results are shown in the table. Conclusions: 1) In this cohort of 80 patients with advanced clear cell or papillary RCC, 47 pt (59%) received systemic treatment immediately after diagnosis and 33 pt (41%) postponed it at least three months. 2) Both groups were similar in age, surgical treatment, metastatic sites and systemic treatments. 3) There was no difference in survival rates with immediate or delayed treatments. [Table: see text] |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|